SavedAdd your journal

Journals / Türk Diş Hekimliği Araştırma Dergisi / 2026 / Cilt: 4 Sayı: 2

Examination of the Relationship of IL-35, RANKL and Osteoprotegerin in the Gingival Crevicular Fluid of Periodontitis and Periodontally Healthy Patients

Periodontitisli ve Periodontal Olarak Sağlıklı Hastaların Diş Eti Oluğu Sıvısında IL-35, RANKL ve Osteoprotegerin İlişkisinin İncelenmesi

Burak Ünal(Beylikdüzü Ağız ve Diş Sağlığı Merkezi)0009-0007-9203-2550
Taner Arabacı(ATATÜRK ÜNİVERSİTESİ, DİŞ HEKİMLİĞİ FAKÜLTESİ, KLİNİK BİLİMLER BÖLÜMÜ, PERİODONTOLOJİ ANABİLİM DALI)0000-0003-0476-1010
Ufuk Kesmez(ATATÜRK ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ ENSTİTÜSÜ, PERİODONTOLOJİ (DR))0009-0009-9016-1150
Ahmet Şanlıdağ(ATATÜRK ÜNİVERSİTESİ, DİŞ HEKİMLİĞİ FAKÜLTESİ, KLİNİK BİLİMLER BÖLÜMÜ, PERİODONTOLOJİ ANABİLİM DALI)0009-0002-2581-2948
Pages
59–74
Publication Date
2025-07-10
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When the study groups were compared in terms of OPG levels, it was concluded that Group S was higher than Group Ps and Group Pd (p<0.001).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this clinical study to evaluate Interleukin-35 (IL-35), receptor activator nuclear facktor (NF)-kB Ligand (RANKL) and osteoprotegerin (OPG) levels in gingival crevicular fluid of peridonititis and periodontally healty individuals and to seearch for a relation between markers and clinacal parameters with each other.
📊
Key Findings & Data:Clinical periodontal measurements of the periodontally healthy (S Group n=20) and periodontitis patients (P Group n=22) were performed and DOS samples were taken with paper strips.
💡
Conclusion & Impact:When the study groups were compared in terms of OPG levels, it was concluded that Group S was higher than Group Ps and Group Pd (p<0.001).
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Diş eti oluğu sıvısı · İnterlökinler · RANK ligandı

Abstract

Aim: The aim of this clinical study to evaluate Interleukin-35 (IL-35), receptor activator nuclear facktor (NF)-kB Ligand (RANKL) and osteoprotegerin (OPG) levels in gingival crevicular fluid of peridonititis and periodontally healty individuals and to seearch for a relation between markers and clinacal parameters with each other. Material and Method: Systemically healthy and nonsmokers were included in this parallel-designed study. Clinical periodontal measurements of the periodontally healthy (S Group n=20) and periodontitis patients (P Group n=22) were performed and DOS samples were taken with paper strips. Two samples were collected separately from the deepest periodontal pocket in the mouth (Pd Group) from individuals with periodontitis and from the disease-free regions of individuals with periodontitis (Ps Group). IL-35, RANKL and OPG levels of the samples were analyzed by “enzyme-linked immunosorbent assay” (ELISA). Results: RANKL levels were found to be significantly higher in the Pd Group than in the Ps Group and Group S (Group S-Pd Group: p=0.001, Ps Group-Pd Group: p=0.017). When the study groups were compared in terms of OPG levels, it was concluded that Group S was higher than Group Ps and Group Pd (p<0.001). In multiple comparisons, IL-35 levels were found to be significantly higher in the Pd Group than in the Ps and S Groups (p<0.001). As a result of multiple comparisons, RANKL/OPG ratio was found to be significantly lower in group S than in Pd and Ps groups (p<0.001). When the relationship between RANKL, OPG and IL-35 levels in the sum of the data of Group S and Group Pd was examined, it was seen that there was a weak negative correlation between OPG and RANKL and IL-35 levels (Respectively; r=-0.398, p<0.011, r= -0.444, p<0.004). A strong positive correlation was found between RANKL and IL-35 levels (r=0.721, p<0.001). When the relationship between RANKL/OPG and IL-35 levels and clinical periodontal parameters was examined, a strong positive correlation was found between IL-35 levels and gingival index, pocket depth on probing and clinical attachment level, and a moderately significant positive correlation with plaque index (Respectively. , r=0.751, r=0.771, r=0.794, r=0.697, p<0.001). A moderately significant positive correlation was found between the RANKL/OPG ratio and plaque index, gingival index, pocket depth on probing, and clinical attachment level (respectively; r=0.617, r=0.689, r=0.616, r=0.632, p<0.001) . Conclusion: In the light of these findings, it is thought that DOS IL-35 level and RANKL/OPG ratio are higher in individuals with periodontitis than in healthy individuals, thus playing a role in the pathogenesis of periodontitis.

Özet

Amaç: Bu klinik çalışmanın amacı, periodontitisli ve peridontal olarak sağlıklı bireylerin diş eti oluğu sıvısında (DOS); İnterlökin-35 (IL-35), reseptör aktivatörü nükleer faktör (NF)-κB ligandı (RANKL) ve osteoprotegerin (OPG) seviyelerinin değerlendirilmesi ayrıca ilgili markerların birbirleriyle ve klinik parametrelerle ilişkisini araştırmaktır. Gereç ve Yöntem: Paralel dizayn edilmiş bu çalışmaya sistemik olarak sağlıklı ve sigara içmeyen bireyler dahil edildi. Periodontal olarak sağlıklı (S Grubu n=20) ve peridontitisli bireylere (P Grubu n=22) ait klinik periodontal ölçümler yapıldı ve DOS örnekleri kağıt stripler ile alındı. Periodontitisli bireylerden ağız içerisinde en derin periodontal cepten (Pd Grubu) ve periodontitisli bireylerin hastalıktan etkilenmeyen bölgelerinden (Ps Grubu) ayrı ayrı iki örnek toplandı. Örneklere ait IL-35, RANKL ve OPG seviyeleri “enzyme-linked immunosorbent assay” (ELISA) ile analiz edildi. Bulgular: Yapılan incelemede RANKL düzeyleri, Pd Grubunda, Ps Grubu ve S Grubuna göre anlamlı derecede daha yüksek olduğu görüldü (S Grubu-Pd Grubu: p=0,001, Ps Grubu- Pd Grubu: p=0,017). OPG düzeyleri açısından çalışma grupları karşılaştırıldığında, S Grubunda, Ps Grubu ve Pd Grubuna göre daha yüksek olduğu sonucuna ulaşıldı (p<0,001). Yapılan çoklu karşılaştırmada, Pd Grubunda IL-35 düzeylerinin Ps ve S Grubuna göre anlamlı derecede daha yüksek olduğu görüldü (p<0,001). Yapılan çoklu karşılaştırma sonucunda, RANKL/OPG oranının S grubunda Pd ve Ps gruplarına göre anlamlı derecede daha düşük olduğu tespit edildi (p<0,001). S Grubu ve Pd Grubunun verileri toplamında RANKL, OPG ve IL-35 düzeylerinin birbirleriyle olan ilişkisi incelendiğinde, OPG ile RANKL ve IL-35 düzeyleri arasında negatif yönlü zayıf bir ilişki olduğu görüldü (Sırasıyla; r=-0,398, p<0,011, r=-0,444, p<0,004). RANKL ve IL-35 düzeyleri arasında ise pozitif yönlü güçlü ilişki bulundu (r=0,721, p<0,001). RANKL/OPG ve IL-35 düzeylerinin klinik periodontal parametreler ile arasındaki ilişkisi incelendiğinde, IL-35 düzeylerinin gingival indeks, sondlamada cep derinliği ve klinik ataçman seviyesi değerleri ile arasında pozitif yönlü güçlü, plak indeksi ile arasında pozitif yönlü orta derecede anlamlı ilişki bulundu (Sırasıyla, r=0,751, r=0,771, r=0,794, r=0,697, p<0,001). RANKL/OPG oranı ile plak indeksi, gingival indeks, sondlamada cep derinliği ve klinik ataçman seviyesi değerleri arasında pozitif yönlü orta derecede anlamlı ilişki saptandı (Sırasıyla; r=0,617, r=0,689, r=0,616, r=0,632, p<0,001). Sonuç: Bu bulgular ışığında DOS IL-35 seviyesi ve RANKL/OPG oranının periodontitisli bireylerde sağlıklı bireylere göre yüksek olmasından dolayı periodontitis hastalığının patogenezinde rol oynadığı düşünülmektedir.

🔖

Cite This Article

Ünal, B., Arabacı, T., Kesmez, U., Şanlıdağ, A. (2025). Examination of the Relationship of IL-35, RANKL and Osteoprotegerin in the Gingival Crevicular Fluid of Periodontitis and Periodontally Healthy Patients. Türk Diş Hekimliği Araştırma Dergisi, Cilt: 4 Sayı: 2, 59–74. https://doi.org/10.58711/turkishjdentres.vi.1578128

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (60)

  1. Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities and host interactions. Nat Rev Microbiol. 2018;16(12):745-59.
  2. Okada H, Murakami S. Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med: an official publication of the American Association of Oral Biologists. 1998;9(3):248-66.
  3. Van Dyke TE. The management of inflammation in periodontal disease. J Periodontol. 2008;79(8 Suppl):1601-8.
  4. Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018;89 Suppl 1:S173-s82.
  5. Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Clin Periodontol. 2018;45 Suppl 20:S149-s61.
  6. Nussbaum G, Shapira L. How has neutrophil research improved our understanding of periodontal pathogenesis? J Clin Periodontol. 2011;38 Suppl 11:49-59.
  7. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol. 2008;79(8 Suppl):1569-76.
  8. Chakravarti A, Raquil MA, Tessier P, Poubelle PE. Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption. Blood. 2009;114(8):1633-44.
  9. Kang W, Hu Z, Ge S. Healthy and Inflamed Gingival Fibroblasts Differ in Their Inflammatory Response to Porphyromonas gingivalis Lipopolysaccharide. Inflammation. 2016;39(5):1842-52.
  10. Rajendran M, Looney S, Singh N, Elashiry M, Meghil MM, El-Awady AR, et al. Systemic Antibiotic Therapy Reduces Circulating Inflammatory Dendritic Cells and 87 Treg- Th17 Plasticity in Periodontitis. J Immunol (Baltimore, Md: 1950). 2019;202(9):2690-9.
  11. Balci Yuce H, Gokturk O, Aydemir Turkal H, Inanir A, Benli I, Demir O. Assessment of local and systemic 25-hydroxyvitamin D, RANKL, OPG, and TNF levels in patients with rheumatoid arthritis and periodontitis. J Oral Sci. 2017;59(3):397-404.
  12. Nagasawa T, Kiji M, Yashiro R, Hormdee D, Lu H, Kunze M, et al. Roles of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in periodontal health and disease. Periodontology 2000. 2007;43:65-84.
  13. Berglundh T, Donati M. Aspects of adaptive host response in periodontitis. J Clin Periodontol. 2005;32 Suppl 6:87-107.
  14. Alvarez C, Rojas C, Rojas L, Cafferata EA, Monasterio G, Vernal R. Regulatory T Lymphocytes in Periodontitis: A Translational View. Mediators Inflamm. 2018;2018:7806912.
  15. Campbell L, Millhouse E, Malcolm J, Culshaw S. T cells, teeth and tissue destruction - what do T cells do in periodontal disease? Mol Oral Microbiol. 2016;31(6):445-56.
  16. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673-82.
  17. Vernal R, Díaz-Zúñiga J, Melgar-Rodríguez S, Pujol M, Diaz-Guerra E, Silva A, et al. Activation of RANKLinduced osteoclasts and memory T lymphocytes by Porphyromonas gingivalis is serotype dependant. J Clin Periodontol. 2014;41(5):451-9.
  18. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Periodontol Invest. 1999;103(9):1345-52.
  19. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunological reviews. 2008;226:248- 62.
  20. Hunter CA. New IL-12-family members: IL-23 and IL- 27, cytokines with divergent functions. Nat Rev Immunol. 2005;5(7):521-31.
  21. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunological reviews. 2004;202:96-105.
  22. Pusic KM, Pusic AD, Kemme J, Kraig RP. Spreading depression requires microglia and is decreased by their M2a polarization from environmental enrichment. Glia. 2014;62(7):1176-94
  23. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al. IL35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507(7492):366-70.
  24. Wirtz S, Billmeier U, McHedlidze T, Blumberg RS, Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology. 2011;141(5):1875-86.
  25. Mitani A, Niedbala W, Fujimura T, Mogi M, Miyamae S, Higuchi N, et al. Increased expression of interleukin (IL)- 35 and IL-17, but not IL-27, in gingival tissues with chronic periodontitis. J Periodontol. 2015;86(2):301-9.
  26. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. European journal of immunology. 2007;37(11):3021-9.
  27. Löe HJTJoP. The gingival index, the plaque index and the retention index systems. 1967;38(6):610-6.
  28. Socransky SS, Haffajee AD. The bacterial etiology of destructive periodontal disease: current concepts. J Periodontol. 1992;63(4 Suppl):322-31.
  29. Grossi SG, Zambon JJ, Ho AW, Koch G, Dunford RG, Machtei EE, et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J Periodontol. 1994;65(3):260-7.
  30. Breivik T, Thrane PS, Murison R, Gjermo P. Emotional stress effects on immunity, gingivitis and periodontitis. Eur J Oral Sci. 1996;104(4 ( Pt 1)):327- 34.
  31. Polson AM, Goodson JMJJoP. Periodontal diagnosis: current status and future needs. 1985;56(1):25-34.
  32. Yan Oosten MA, Mikx FH, Renggli HH. Microbial and clinical measurements of periodontal pockets during sequential periods of non-treatment, mechanical debridement and metronidazole therapy. J Clin Periodontol. 1987;14(4):197-204.
  33. Lindhe J, Westfelt E, Nyman S, Socransky SS, Haffajee AD. Long-term effect of surgical/non-surgical treatment of periodontal disease. J Clin Periodontol. 1984;11(7):448-58.
  34. Armitage GCJP. Analysis of gingival crevice fluid and risk of progression of periodontitis. 2004;34(1):109-19.
  35. Lamster IB, Ahlo JK. Analysis of gingival crevicular fluid as applied to the diagnosis of oral and systemic diseases. Ann N Y Acad Sci. 2007;1098:216-29.
  36. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566- 9.
  37. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11(12):1093-101.
  38. Kalburgi NB, Muley A, Shivaprasad BM, Koregol AC. Expression profile of IL-35 mRNA in gingiva of chronic periodontitis and aggressive periodontitis patients: a semiquantitative RT-PCR study. Dis Markers. 2013;35(6):819-23.
  39. Köseoğlu S, Sağlam M, Pekbağrıyanık T, Savran L, Sütçü R. Level of Interleukin35 in Gingival Crevicular Fluid, Saliva, and Plasma in Periodontal Disease and Health. J Periodontol. 2015;86(8):964-71.
  40. Kamiya Y, Kikuchi T, Goto H, Okabe I, Takayanagi Y, Suzuki Y, et al. IL-35 and RANKL Synergistically Induce Osteoclastogenesis in RAW264 Mouse Monocytic Cells. International journal of molecular sciences. 2020;21(6).
  41. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, et al. IL- 35 is a novel responsive antiinflammatory cytokine--a new system of categorizing anti-inflammatory cytokines. PloS one. 2012;7(3):e33628.7
  42. Raj SC, Panda SM, Dash M, Patnaik K, Mohanty D, Katti N, et al. Association of Human Interleukin-35 Level in Gingival Crevicular Fluid and Serum in Periodontal Health, Disease, and after Nonsurgical Therapy: A Comparative Study. Contemp Clin Dent. 2018;9(2):293-7.
  43. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A. 1990;87(18):7260-4.
  44. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597-602.
  45. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165-76.
  46. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-19.
  47. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl). 2001;79(5-6):243-53.
  48. Cardoso CR, Garlet GP, Crippa GE, Rosa AL, Júnior WM, Rossi MA, et al. Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal disease. Oral Microbiol Immunol. 2009;24(1):1-6.
  49. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenende Roo CJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol. (Baltimore, Md: 1950). 2003;170(5):2655-62
  50. Li Y, Li D, Li Y, Wu S, Jiang S, Lin T, et al. Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes. Osteoporos Int. 2016;27(4):1537-46.
  51. Culshaw S, McInnes IB, Liew FYJJocp. What can the periodontal community learn from the pathophysiology of rheumatoid arthritis? 2011;38:106-13.
  52. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res. 2004;83(2):166-9
  53. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Töz H, et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Periodontol. 2007;34(5):370-6.
  54. López Roldán A, García Giménez JL, Alpiste Illueca F. Impact of periodontal treatment on the RANKL/OPG ratioin crevicular fluid. PloS one. 2020;15(1):e0227757.
  55. Yakar N, Guncu GN, Akman AC, Pınar A, Karabulut E, Nohutcu RM. Evaluation of gingival crevicular fluid and peri-implant crevicular fluid levels of sclerostin, TWEAK, RANKL and OPG. Cytokine. 2019;113:433-9.
  56. Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-κB Ligand in Periodontitis. J Periodontol. 2015;86(12):1396- 404.
  57. Baltacıoğlu E, Kehribar MA, Yuva P, Alver A, Atagün OS, Karabulut E, et al. Total oxidant status and bone resorption biomarkers in serum and gingival crevicular fluid of patients with periodontitis. J Periodontol. 2014;85(2):317-26.
  58. Rajendran M, Looney S, Singh N, Elashiry M, Meghil MM, El-Awady AR, et al. Systemic Antibiotic Therapy Reduces Circulating Inflammatory Dendritic Cells and 87 Treg- Th17 Plasticity in Periodontitis. J Immunol (Baltimore, Md: 1950). 2019;202(9):2690-9.
  59. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597-602.
  60. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenende Roo CJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol. (Baltimore, Md: 1950). 2003;170(5):2655-62